中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2014年
35期
45-47
,共3页
急性冠脉综合征%经皮冠状动脉介入%阿托伐他汀%疗效%炎症因子
急性冠脈綜閤徵%經皮冠狀動脈介入%阿託伐他汀%療效%炎癥因子
급성관맥종합정%경피관상동맥개입%아탁벌타정%료효%염증인자
Acute coronary syndrome%Percutaneous coronary intervention%Atovatatin%Curative effect%Inflammatory factor
目的：探讨不同剂量阿托伐他汀对急性冠状动脉综合征患者行经皮冠状动脉介入(PCI)术后疗效及炎症因子的影响。方法选取2012年1月~2013年8月择期行PCI术的急性冠状动脉综合征患者102例，随机分为阿托伐他汀钙10 mg组(A组)和20 mg组(B组)，每组51例。在患者择期行PCI术前、术后抽血测患者血脂[总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和三酰甘油(TG)]和炎症因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)]水平，记录术后30、180 d时主要心脏不良事件发生情况。结果 A、B两组在PCI术前后TC、LDL-C、TG比较，差异无统计学意义(P>0.05)；组内PCI术后与术前比较，差异有统计学意义(P<0.05)。 A、B两组血清TNF-α、IL-6、hs-CRP术前比较，差异无统计学意义(P>0.05)，术后7、30 d差异有统计学意义(P<0.05)。两组主要心脏不良事件发生率比较，差异无统计学意义(P>0.05)。结论急性冠状动脉综合征患者行择期PCI术时两种剂量的阿托伐他汀均安全有效，均能明显降低术后炎症因子水平，抗炎作用可独立于降脂作用以外。
目的：探討不同劑量阿託伐他汀對急性冠狀動脈綜閤徵患者行經皮冠狀動脈介入(PCI)術後療效及炎癥因子的影響。方法選取2012年1月~2013年8月擇期行PCI術的急性冠狀動脈綜閤徵患者102例，隨機分為阿託伐他汀鈣10 mg組(A組)和20 mg組(B組)，每組51例。在患者擇期行PCI術前、術後抽血測患者血脂[總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)和三酰甘油(TG)]和炎癥因子[超敏C反應蛋白(hs-CRP)、腫瘤壞死因子α(TNF-α)、白細胞介素-6(IL-6)]水平，記錄術後30、180 d時主要心髒不良事件髮生情況。結果 A、B兩組在PCI術前後TC、LDL-C、TG比較，差異無統計學意義(P>0.05)；組內PCI術後與術前比較，差異有統計學意義(P<0.05)。 A、B兩組血清TNF-α、IL-6、hs-CRP術前比較，差異無統計學意義(P>0.05)，術後7、30 d差異有統計學意義(P<0.05)。兩組主要心髒不良事件髮生率比較，差異無統計學意義(P>0.05)。結論急性冠狀動脈綜閤徵患者行擇期PCI術時兩種劑量的阿託伐他汀均安全有效，均能明顯降低術後炎癥因子水平，抗炎作用可獨立于降脂作用以外。
목적：탐토불동제량아탁벌타정대급성관상동맥종합정환자행경피관상동맥개입(PCI)술후료효급염증인자적영향。방법선취2012년1월~2013년8월택기행PCI술적급성관상동맥종합정환자102례，수궤분위아탁벌타정개10 mg조(A조)화20 mg조(B조)，매조51례。재환자택기행PCI술전、술후추혈측환자혈지[총담고순(TC)、저밀도지단백담고순(LDL-C)화삼선감유(TG)]화염증인자[초민C반응단백(hs-CRP)、종류배사인자α(TNF-α)、백세포개소-6(IL-6)]수평，기록술후30、180 d시주요심장불량사건발생정황。결과 A、B량조재PCI술전후TC、LDL-C、TG비교，차이무통계학의의(P>0.05)；조내PCI술후여술전비교，차이유통계학의의(P<0.05)。 A、B량조혈청TNF-α、IL-6、hs-CRP술전비교，차이무통계학의의(P>0.05)，술후7、30 d차이유통계학의의(P<0.05)。량조주요심장불량사건발생솔비교，차이무통계학의의(P>0.05)。결론급성관상동맥종합정환자행택기PCI술시량충제량적아탁벌타정균안전유효，균능명현강저술후염증인자수평，항염작용가독립우강지작용이외。
Objective To investigate the influence of different doses of atorvastatin on efficacy and inflammatory factors after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome. Methods 102 patients with acute coronary syndrome undergoing PCI surgery in our hospital from January 2012 to August 2013 were selected and randomly divided into 10 mg atorvastatin calcium group (group A) and 20 mg atorvastatin calcium group (group B),51 cases in each group.Before and after PCI,serum lipid [total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG)] and inflammatory cytokines [high-sensitivity C-reactive protein (hs-CRP),tumor necrosis factor-α (TNF-α),interleukin -6 (IL-6)] level was measured,the incidence of major adverse cardiac events postoperative 30 d and 180 d were recorded. Results There was no significant difference about TC,LDL-C,TG between group A and group B before and after PCI operation (P>0.05);There was significant difference after PCI operation compared with before PCI operation in each group (P<0.05).There was no significant difference about TNF-α,IL-6,hs-CRP in group A and group B before PCI operation (P>0.05);there was significant difference after 7 d and 30 d PCI operation (P<0.05).There was no significant difference on rate of major adverse cardiac event between the two groups (P>0.05). Conclusion Two doses of atorvastatin is safe and effective in patients with acute coronary syndrome undergoing PCI,can significantly de-crease the level of inflammatory factors after PCI operation,but independent of the lipid-lowering effect outside.
